1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
StageZero Life Sciences Ltd.

StageZero Life Sciences Ltd.

SZLS.TO
StageZero Life Sciences Ltd.CA flagToronto Stock Exchange
0.04
CAD
- -
- -
4.94MMarket Cap
StageZero Life Sciences Ltd.
SZLS.TO
(Toronto Stock Exchange)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
1.78
0.94
0.82
0.12
0.05
0.12
0.03
0.38
0.05
0.13
0.03
0.01
- -
0.09
0.07
0.04
0.02
Revenue per Share
-7.89
-8.74
-4.02
-2.99
-2.34
-2.23
-2.07
-1.17
-0.9
-0.72
-0.24
-0.22
-0.1
-0.15
-0.11
-0.11
-0.1
Basic EPS, GAAP
-8.69
-6.47
-3.48
-1.53
-1.52
-1.78
-1.02
-0.27
-0.26
-0.46
-0.32
-0.2
-0.14
-0.07
-0.13
-0.04
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-27.33
-30.87
-37.48
-36.47
-31.77
-29.09
-15.97
-12.67
-12.14
-10.54
-1.25
-1.01
-0.5
-0.33
-0.16
-0.22
-0.2
Book Value per Share
10.88
1.4
1.88
-0.09
-0.18
2.22
0.41
0.36
-0.27
-0.7
-0.34
-0.32
-0.13
-0.03
-0.07
-0.08
-0.08
Tangible Book Value per Share
1
1
1
2
2
2
4
6
7
8
12
17
34
45
71
99
121
Basic Weighted Avg Shares
2
1
1
- -
- -
- -
- -
2
- -
1
- -
- -
- -
4
5
4
3
Sales/Revenue/Turnover
-475.65
-948.51
-447.98
-2,098.59
-3,788.62
-1,552.42
-4,153.89
-99.07
-874.93
-404.56
-1,252.9
-2,510.83
-3,567.44
-80.81
-160.43
-206.43
-153.57
Operating Margin (%)
1
1
1
1
1
- -
- -
- -
- -
- -
- -
1
- -
- -
1
- -
- -
Depreciation Expense
-10
-11
-5
-5
-4
-5
-9
-7
-6
-6
-3
-4
-3
-7
-7
-11
-13
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-444.43
-926.34
-488.19
-2,395.13
-4,445.32
-1,804.08
-7,119.98
-312.89
-1,846.73
-560.76
-715.96
-1,986.66
-2,510.24
-165.32
-147.67
-300.79
-418.65
Profit Margin (%)
11
- -
2
2
2
8
2
2
-2
-6
-3
-5
-4
2
-2
-7
-8
Working Capital
1
1
3
4
4
4
- -
- -
- -
- -
1
1
1
1
1
1
1
LT Debt
14
2
2
- -
- -
5
2
2
-2
-5
-4
-6
-4
-1
3
-8
-9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
1
1
1
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
106
123
124
Market Capitalization
8
5
5

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
8
8
Payables & Accruals
6
7
7
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-81.79%
-147.98%
-371.69%
Free Cash Flow
19.35%
24.21%
-61.24%
Net Income, GAAP
16.55%
35.66%
52.53%
Sales/Revenue/Turnover
452.17%
562%
-25.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1
1
1
1
4
2023
- -
- -
1
1
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.01
-0.01
- -
- -
-0.11
2023
-0.01
- -
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
H.U. Group Holdings, Inc. (4544.T)
Krsnaa Diagnostics Limited (KRSNAA.BO)
Joinn Laboratories(China)Co.,Ltd. (6127.HK)
Many Bright Ideas Technologies Inc. (MBGNF)
Medivolve Inc. (4NC.F)
Diaceutics PLC (DIUXF)
Business
StageZero Life Sciences Ltd. (SZLS.TO) develops and commercializes advanced diagnostic technologies focused on early cancer detection and management through non-invasive blood-based testing. The company offers its flagship Aristotle platform, which utilizes machine learning algorithms and multimodal biomarkers to analyze blood samples for detecting multiple cancer types, including colorectal, breast, lung, and bladder cancers; its services include laboratory testing, physician consultations, and patient monitoring programs delivered through accredited labs and healthcare networks. Headquartered in Richmond Hill, Ontario, Canada, and founded in 1998 as a life sciences innovator, StageZero operates primarily in North America with expanding clinical partnerships in the United States and Canada, targeting oncologists, primary care providers, and health systems seeking precision diagnostics. The company's core products encompass the Aristotle Colon Cancer Test for early-stage colorectal screening; Aristotle Universal Cancer Test for pan-cancer detection across 17+ indications; and supportive services such as AI-driven risk stratification and longitudinal monitoring tools. StageZero serves the oncology diagnostics segment, emphasizing liquid biopsy alternatives to invasive procedures for high-risk populations aged 45 and older. In the past two years, StageZero has pursued strategic expansions including enhanced clinical validation studies for its Aristotle platform in 2024-2025 and new distribution alliances with regional labs to broaden U.S. market access; no major funding rounds, acquisitions, or name changes were reported in this period.